Business Description
Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Staten Island, New York. It focuses on developing a new class of small molecule antibiotics to treat difficult-to-treat bacterial infections caused by priority pathogens. The company's proprietary approach targets the DNA polymerase IIIC enzyme to inhibit DNA replication in Gram-positive bacteria.
Everything on Acurx Pharmaceuticals, Inc.
Financials
View financials ↗
YoY growth
—
Operating margin
—
Direction
—
Gross margin
—
Net margin
—
Earnings Transcripts
View all transcripts ↗Leadership & board
View leadership ↗
David P. Luci — Co-Founder, President & Chief Executive Officer, Director
View full profile ↗
Robert J. DeLuccia — Co-Founder & Executive Chairman, Director
View full profile ↗
Robert G. Shawah — Co-Founder & Chief Financial Officer
View full profile ↗
Carl V. Sailer — Director
View full profile ↗
Thomas Harrison — Director
View full profile ↗
Joseph C. Scodari — Director
View full profile ↗
Jack H. Dean — Director
View full profile ↗
James Donohue — Director
View full profile ↗
Named Competitors
Merck & Co.Nestle Health ScienceSeres TherapeuticsFerring PharmaceuticalsCrestone
Customer Concentration
Acurx is a pre-revenue, clinical-stage biopharmaceutical company with no products approved for commercial sale and has not generated any product revenue to date; accordingly, it has no commercial customers or customer concentration.
Recent SEC Filings
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.